(Q43750729)

26 November 2017

title

Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana (English)

1 reference

26 November 2017

main subject

Streptococcus pneumoniae

1 reference

1 reference

Kays MB

1

1 reference

26 November 2017

Denys GA

series ordinal

2

1 reference

26 November 2017

publication date

1 August 2001

1 reference

Diagnostic Microbiology and Infectious Disease

26 November 2017

published in

1 reference

26 November 2017

volume

40

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

193-198

1 reference

Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective U.S. study

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900277-2

7 January 2021

10.1016/S0732-8893(01)00277-2

Identifiers

DOI

1 reference

26 November 2017

1 reference